Background. DAL is lipoglycopeptide antibiotic which is a highly protein bound (93%) with a long elimination half-life in plasma. DAL exhibits activity against Grampositive organisms, including MRSA, with an in vitro MIC 90 of 0.06 mg/ml. The objective of this study was to characterize the PK of DAL in bone and associated tissues in patients undergoing joint surgery.
used to determine the total amount of bone tissue and to estimate the amount of DAL in bone.
Results. DAL concentrations in bone, synovial fluid, synovial tissue, and skin exceeded the DAL MIC 90 against S. aureus of 0.06 mg/mL. DAL concentrations in bone appeared to remain relatively constant for a period of 14 days after a single dose. The mean bone:plasma AUC penetration ratio was 13.9%. 
